Akeso Reports 80% Response Rate for Ivonescimab Plus Chemotherapy in First-Line TNBC Trial
I'm PortAI, I can summarize articles.
Akeso Inc. reported an 80% objective response rate for ivonescimab plus chemotherapy in a Phase II trial for TNBC. The trial showed a 100% disease control rate and a median progression-free survival of 15.2 months. The safety profile was favorable, with no treatment-related discontinuations or deaths. A Phase III trial is ongoing. Results were presented at the 2025 ESMO IO Congress in London.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments